Literature DB >> 19671590

CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.

Jesús Oteo1, Beatriz Orden, Verónica Bautista, Oscar Cuevas, Margarita Arroyo, Rocío Martínez-Ruiz, María Pérez-Vázquez, Marta Alcaraz, Silvia García-Cobos, José Campos.   

Abstract

OBJECTIVES: To describe trends in fosfomycin resistance in urinary isolates of Escherichia coli producing extended-spectrum beta-lactamases (ESBLs) in relation to fosfomycin consumption and to characterize representative fosfomycin-resistant isolates.
METHODS: In 2007-08, an unexpected increase in fosfomycin resistance in ESBL-producing urinary E. coli was observed. Laboratory records were reviewed and a prospective surveillance study was initiated on all urinary tract infections caused by ESBL-producing, fosfomycin-resistant E. coli. bla(ESBL) types, phylogroups, genetic environment and afa/dra operon were determined by PCR and sequencing. Molecular epidemiology was analysed by PFGE and multilocus sequence typing. To elucidate possible mechanisms of fosfomycin resistance, uhpT, glpT, uhpA, ptsI, cyaA and murA genes were analysed. Fosfomycin consumption was determined as recommended by WHO.
RESULTS: From 2004 to 2008, fosfomycin consumption increased by 50%, while fosfomycin resistance in ESBL producers increased from 2.2% to 21.7%. Of 26 isolates studied, 24 produced CTX-M-15 and belonged to the O25b-ST131-phylogroup B2 clonal strain. PFGE revealed two clusters. Cluster I included 18 isolates, 16 of them indistinguishable from strains producing CTX-M-15 previously described in Madrid. The five isolates of Cluster II had the IS26 linked to bla(CTX-M-15) and the afa/dra operon. In Cluster I isolates, no mutations in glpT, uhpT, uhpA, ptsI, cyaA and murA were detected. Cluster II isolates showed a 15 bp deletion (A(169)-C(183)) in uhpA.
CONCLUSIONS: Fosfomycin resistance in urinary E. coli has increased due to the acquisition of this resistance by a previously circulating CTX-M-15-producing E. coli O25b-ST131-phylogroup B2 strain. This happened during a period when the use of fosfomycin increased by 50%.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671590     DOI: 10.1093/jac/dkp288

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China.

Authors:  Jianxia Hou; Xianhui Huang; Yuting Deng; Liangying He; Tong Yang; Zhenling Zeng; Zhangliu Chen; Jian-Hua Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

2.  Role of the CpxAR two-component signal transduction system in control of fosfomycin resistance and carbon substrate uptake.

Authors:  Kumiko Kurabayashi; Yuko Hirakawa; Koichi Tanimoto; Haruyoshi Tomita; Hidetada Hirakawa
Journal:  J Bacteriol       Date:  2013-10-25       Impact factor: 3.490

Review 3.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 4.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

5.  Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.

Authors:  G Bonkat; G Müller; O Braissant; R Frei; S Tschudin-Suter; M Rieken; S Wyler; T C Gasser; A Bachmann; A F Widmer
Journal:  World J Urol       Date:  2013-01-29       Impact factor: 4.226

6.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

Review 7.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 8.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

9.  Antimicrobial stewardship - can we afford to do without it?

Authors:  Anna Aryee; Nicholas Price
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

10.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.